Kathleen N. Moore
凯瑟琳·摩尔
MD, MS
Associate Director for Clinical Research, Professor of Gynecologic Oncology临床研究副主任，妇科肿瘤学教授
👥Biography 个人简介
Dr. Kathleen Moore is a leading ovarian cancer researcher at University of Oklahoma, renowned for her work on PARP inhibitors and anti-angiogenic combination strategies. She has led major trials including PAOLA-1 and PRIMA, shaping first-line ovarian cancer treatment globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
First-Line Maintenance Therapy
Led PRIMA trial establishing niraparib as first-line maintenance in advanced ovarian cancer, showing significant PFS benefit regardless of biomarker status.
Combination Maintenance Strategies
Investigated olaparib plus bevacizumab combination (PAOLA-1), demonstrating superior outcomes in HRD-positive ovarian cancer patients after platinum-based chemotherapy.
Representative Works 代表性著作
Niraparib in Newly Diagnosed Ovarian Cancer (PRIMA)
New England Journal of Medicine (2019)
Demonstrated niraparib maintenance significantly improved PFS in advanced ovarian cancer following platinum-based chemotherapy.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1)
New England Journal of Medicine (2019)
Showed clinical benefit of olaparib-bevacizumab combination in HRD-positive advanced ovarian cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Ana Oaknin
Vall d'Hebron University Hospital
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
Vicky Makker
Memorial Sloan Kettering Cancer Center
关注 凯瑟琳·摩尔 的研究动态
Follow Kathleen N. Moore's research updates
留下邮箱，当我们发布与 Kathleen N. Moore（Stephenson Cancer Center, University of Oklahoma）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment